We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
-4%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$3.61B
AUM Growth
-$467M
(-11%)
Cap. Flow
-$113M
Cap. Flow
% of AUM
-3.11%
Top 10 Holdings %
Top 10 Hldgs %
67.4%
Holding
42
New
6
Increased
7
Reduced
10
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$135M |
| 2 |
CVS Health
CVS
|
+$93.8M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$70.8M |
| 4 |
Medtronic
MDT
|
+$32.8M |
| 5 |
argenx
ARGX
|
+$27.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tenet Healthcare
THC
|
+$200M |
| 2 |
Biogen
BIIB
|
+$86.3M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$55.9M |
| 4 |
Universal Health Services
UHS
|
+$53.1M |
| 5 |
Myriad Genetics
MYGN
|
+$46.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 70.02% |
| 2 | Miscellaneous | 28.94% |
| 3 | Consumer Staples | 1.05% |
| 4 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BKDT
26
DELISTED
Brookdale Senior Living Inc. 7.00% Tangible Equity Units
BKDT
| $23.2M | 0.64% |
250,000
| – | – |
|
|
BCYC
27
Bicycle Therapeutics
BCYC
$257M
| $18.5M | 0.51% |
915,000
+465,000
| +103% | +$10.5M |
|
28
OraSure Technologies
OSUR
$239M
| $18.1M | 0.5% |
4,250,000
| – | – |
|
29
Inogen
INGN
$138M
| $16.3M | 0.45% |
2,000,000
| – | – |
|
30
MoonLake Immunotherapeutics
MLTX
$1.04B
| $15.6M | 0.43% |
+355,000
| New | +$15M |
|
31
AnaptysBio
ANAB
$1.62B
| $12.5M | 0.35% |
+500,000
| New | +$11.6M |
|
32
Replimune Group
REPL
$1.23B
| $12.2M | 0.34% |
1,350,000
-1,400,000
| -51% | -$9.76M |
|
33
Evolent Health
EVH
$423M
| $11.9M | 0.33% |
+625,000
| New | +$16M |
|
34
Theravance Biopharma
TBPH
$885M
| $8.48M | 0.23% |
1,000,000
| – | – |
|
35
SkinHealth Systems
SKIN
$87.8M
| $6.72M | 0.19% |
3,500,000
| – | – |
|
|
CVAC
36
DELISTED
CureVac
CVAC
| $1.87M | 0.05% |
550,000
-1,200,000
| -69% | -$3.92M |
|
37
Genmab
GMAB
$21B
| $1.26M | 0.03% |
50,000
| – | – |
|
|
38
Biogen
BIIB
$31.9B
| – | – |
-400,000
| Closed | -$86.3M |
|
39
Collegium Pharmaceutical
COLL
$711M
| – | – |
-852,900
| Closed | -$33.1M |
|
40
Puma Biotechnology
PBYI
$477M
| – | – |
-1,650,000
| Closed | -$8.74M |
|
41
Peloton Interactive
PTON
$2.13B
| – | – |
-4,500,000
| Closed | -$19.3M |
|
|
42
Tenet Healthcare
THC
$21B
| – | – |
-1,900,000
| Closed | -$200M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q2 2024 Portfolio in Review
As of Q2 2024, Camber Capital Management held 42 positions worth $3.61B, down 11% from $4.08B the previous quarter. Its ten largest holdings account for 67% of the portfolio.
Camber Capital Management withdrew a net $113M in Q2 2024, closing 5 positions and reducing 10 holdings. Its most notable exit was Tenet Healthcare, an estimated $200M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 68% a quarter earlier, followed by Miscellaneous and Consumer Staples.
Against the trend, Camber Capital Management opened a new position in Humana worth $149M.
- Camber Capital Management's largest Q2 2024 buy was Humana: 400,000 shares worth $149M.
- Camber Capital Management added most to BioMarin Pharmaceuticals in Q2 2024, an estimated $70.8M increase.
- Camber Capital Management's biggest Q2 2024 reduction was Sarepta Therapeutics, cutting an estimated $55.9M.
- Camber Capital Management fully exited Tenet Healthcare in Q2 2024, selling an estimated $200M.
- Camber Capital Management's ten largest holdings make up 67% of its $3.61B portfolio in Q2 2024.
- Camber Capital Management opened 6 new positions and closed 5 in Q2 2024.
- Camber Capital Management's portfolio value fell 11% quarter-over-quarter to $3.61B.
Based on Camber Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.